文献速递糖尿病

新型每周一次基础胰岛素Fc在1型糖尿病患者中达到与德谷胰岛素相似的血糖控制且安全性相当

Novel Once-Weekly Basal Insulin Fc Achieved Similar Glycemic Control With a Safety Profile Comparable to Insulin Degludec in Patients With Type 1 Diabetes.
PubMed 文献 · Diabetes Care · 2023-01-01

这项2期随机、平行、开放标签研究纳入265例使用每日多次注射的1型糖尿病患者,按1:1随机接受每周一次基础胰岛素Fc(BIF)或每日一次德谷胰岛素治疗26周。主要终点HbA1c自基线的变化显示BIF非劣效于德谷胰岛素(治疗差异0.17%,90%CI 0.01,0.32;P=0.07),低血糖发生率两组无统计学显著差异,严重不良事件发生情况相似。

要点

  • 每周一次BIF在1型糖尿病患者中HbA1c变化非劣效于每日一次德谷胰岛素。
  • BIF组空腹血糖显著高于德谷胰岛素组(158.8 mg/dL vs 143.2 mg/dL;P=0.003)。
  • 两组24小时内CGM derived低血糖发生率无统计学显著差异,严重不良事件相似。

核心结论

  • 每周一次BIF在1型糖尿病患者中显示出与每日一次德谷胰岛素非劣效的血糖控制(治疗差异0.17% favoring德谷胰岛素),低血糖或其他安全性发现无差异。

研究设计与样本

  • 随机、平行、开放标签2期研究,纳入265例使用每日多次注射的1型糖尿病患者,按1:1随机接受每周一次BIF或每日一次德谷胰岛素治疗26周。
  • 两组均滴定至空腹血糖80-100 mg/dL。
  • 主要终点为HbA1c自基线至第26周的变化(非劣效界值0.4%)。

主要发现

  • 第26周时,BIF组HbA1c自基线变化非劣效于德谷胰岛素组,治疗差异0.17%(90%CI 0.01,0.32;P=0.07),favoring对照药。
  • 第26周时目标范围内时间百分比(TIR,70-180 mg/dL)BIF组为56.1%,德谷胰岛素组为58.9%(P=0.112)。
  • 空腹血糖BIF组显著高于德谷胰岛素组(158.8 mg/dL vs 143.2 mg/dL;P=0.003)。
  • 治疗期间24小时内CGM derived低血糖发生率BIF组与德谷胰岛素组在1级(P=0.960)或2级(P=0.517)低血糖方面无统计学显著差异。
  • 严重不良事件发生情况BIF组与德谷胰岛素组相似。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Basal Insulin Fc (BIF; insulin efsitora alfa; LY3209590), a fusion protein combining a novel single-chain insulin variant with a human IgG Fc domain, is designed for once-weekly basal insulin administration. This phase 2 study assessed safety and efficacy of BIF versus degludec in 265 patients with type 1 diabetes (T1D) using multiple daily injections. RESEARCH DESIGN AND METHODS: During this randomized, parallel, open-label study, patients with T1D were randomized (1:1) to receive BIF once weekly or degludec once daily over the 26-week treatment period. Both groups were titrated to a fasting glucose level of 80-100 mg/dL. The primary end point was HbA1c change from baseline to week 26 (noninferiority margin, 0.4%). Secondary end points included percent time in range (TIR) (70-180 mg/dL), continuous glucose monitoring (CGM) fasting glucose (FG) level, and rate of hypoglycemia. RESULTS: After 26 weeks, patients receiving BIF had noninferior HbA1c change from baseline versus those receiving degludec, with a statistically significant treatment difference of 0.17% (90% CI 0.01, 0.32; P = 0.07) favoring the comparator. Percent TIR was similar for patients in the BIF (56.1%) and degludec (58.9%; P = 0.112) groups at week 26. FG values were significantly higher for patients receiving BIF (158.8 mg/dL) versus degludec (143.2 mg/dL; P = 0.003). Rates of CGM-derived hypoglycemia were not statistically significantly different for BIF and degludec over 24 h for level 1 (P = 0.960) or level 2 (P = 0.517) hypoglycemia during the treatment period. Occurrence of serious adverse events was similar between the BIF and degludec groups. CONCLUSIONS: Once-weekly BIF demonstrated noninferior glycemic control to once-daily degludec (treatment difference: 0.17% favoring degludec) and no difference in hypoglycemia or other safety findings in patients with T1D.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Kazda CM, Bue-Valleskey JM, Chien J, et al. Novel Once-Weekly Basal Insulin Fc Achieved Similar Glycemic Control With a Safety Profile Comparable to Insulin Degludec in Patients With Type 1 Diabetes. Diabetes Care. 2023. PMID: 36920867. doi:10.2337/dc22-2395

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。